AbbVie Reports Three-Year UltIMMa Data for Skyrizi in Plaque Psoriasis

AbbVie today presented three-year follow-up data from the Phase 3 UltIMMa-1 and UltIMMa-2 trials evaluating Skyrizi (risankizumab) in patients with moderate-to-severe plaque psoriasis. The data showed that Skyrizi maintained significant skin clearance over three years of treatment, with approximately 70% of patients achieving PASI 90 response at three years.